


TAI-1

Cat. No.:	HY-B0790
CAS No.:	1334921-03-7
Molecular Formula:	C ₂₄ H ₂₁ N ₃ O ₃ S
Molecular Weight:	431.51
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TAI-1, an orally active anticancer agent, is a highly potent first-in-class Hec1 inhibitor, with a GI ₅₀ of 13.48 nM in K562 cells ^[1] .									
IC₅₀ & Target	GI ₅₀ : 13.48 nM (in K562 cells) ^[1] .									
In Vitro	<p>TAI-1 disrupts Hec1-Nek2 protein interaction, leads to Nek2 degradation, induces significant chromosomal misalignment in metaphase, and induces apoptotic cell death^[1].</p> <p>TAI-1 induces cancer cell death through the induction of cleavage of apoptotic proteins Caspase 3 and PARP and degradation of anti-apoptotic proteins MCL-1 and suggests that TAI-1 leads to activation of the apoptotic pathways^[1].</p> <p>TAI-1 is effective in many cancer cells, such as Chronic myeloid leukemia, Cervical cancer, Breast, metastatic-pleural, invasive ductal carcinoma, Acute myeloid leukemia, Myelogenous leukemia, Colorectal carcinoma cells, with GI₅₀ less than 100 nM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>TAI-1 (20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID) inhibits tumor growth in multiple cancer xenograft models^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C.B-17 SCID mice (6-7 weeks, 21-24 g)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID.</td> </tr> <tr> <td>Administration:</td> <td>QDx28 cycles.</td> </tr> <tr> <td>Result:</td> <td>Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted for the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.</td> </tr> </table>		Animal Model:	C.B-17 SCID mice (6-7 weeks, 21-24 g) ^[1] .	Dosage:	20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID.	Administration:	QDx28 cycles.	Result:	Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted for the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.
Animal Model:	C.B-17 SCID mice (6-7 weeks, 21-24 g) ^[1] .									
Dosage:	20 mg/kg intravenously IV/ or 150 mg/kg per oral PO/BID.									
Administration:	QDx28 cycles.									
Result:	Led to significant tumor growth retardation in Huh-7 and modest tumor inhibition was noted for the Colo205 and MDA-MB-231 models. Did not lead to any loss in body weight.									

REFERENCES

[1]. Lynn Y L Huang, et al. Characterization of the Biological Activity of a Potent Small Molecule Hec1 Inhibitor TAI-1. J Exp Clin Cancer Res. 2014 Jan 9;33(1):6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA